• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2015

  • ID: 1537322
  • June 2015
  • Region: Global
  • Bioseeker

The Alpha6 Beta4 Integrin signaling pathway activates the PI 3-kinase/Akt, MAPK/NFkB and SMAD signaling modules.
There are today 343 companies plus partners developing 464 Alpha6Beta4 integrin pathway targeting drugs in 1712 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 201 drugs. Alpha6 Beta4 Integrin Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 179 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 176 out of the 177 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 40 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

- READ MORE >

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)